loader2
Partner With Us NRI

Company details

82.50
84.40
70.00
155.00
6M Return -24.36%
1Y Return -3.61%
Mkt Cap.(Cr) 207.51
Volume 64
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 64

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 79.15 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 30,916.98 -44,588.21
LAST 3M 79,590.49 -44,523.79
LAST 6M 143,408.31 -191,400.91
LAST 12M 204,102.65 -163,801.53
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
No data found

Information

  • About Company
  • Company Info
  • Listing Info
0
66.41%
29.5983
0%
0%
Description
  • Brooks Laboratories Ltd is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically. The company`s manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India. The company`s major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd. Brooks Laboratories Ltd was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (R&D) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production. In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal & Rajesh Mahajan. In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF. In August 2011, Brooks Laboratories raised Rs. 63 crore from the public through IPO. The shares of the company got listed on the stock exchanges with effect from 5 September 2011. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity. On 7 March 2017, Brooks Laboratories` world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review. The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. During the year ended 31 March 2018, the company operated the Baddi plant at 90% capacity except for 3 months from June to August due to upgradation of injectable facility in Baddi. The company commenced production in August 2017 in new renovated building at Baddi plant with almost double the capacity of previous line.

Read More

No Data Found

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 533543
NSE Code : BROOKS
Book Closure Date (Month) : Sep
BSE Group : T
ISIN : INE650L01011

ICICIdirect Brooks Laboratories Ltd FAQ

You can buy Brooks Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Brooks Laboratories Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2022 10:22 AM the closing price of Brooks Laboratories Ltd was ₹ 84.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 17, 2022 10:22 AM, the market cap of Brooks Laboratories Ltd stood at ₹ 207.51.
The latest PE ratio of Brooks Laboratories Ltd as of May 17, 2022 10:22 AM is 0
The latest PB ratio of Brooks Laboratories Ltd as of May 17, 2022 10:22 AM is 0.36
The 52-week high of Brooks Laboratories Ltd is ₹ 155.00 while the 52-week low is ₹ 70.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE